{"name":"Centre Georges Francois Leclerc","slug":"centre-georges-francois-leclerc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"FOLFIRINOX treatment","genericName":"FOLFIRINOX treatment","slug":"folfirinox-treatment","indication":"Metastatic pancreatic cancer","status":"phase_2"}]}],"pipeline":[{"name":"FOLFIRINOX treatment","genericName":"FOLFIRINOX treatment","slug":"folfirinox-treatment","phase":"phase_2","mechanism":"FOLFIRINOX is a chemotherapy regimen that combines four different drugs to target rapidly dividing cancer cells.","indications":["Metastatic pancreatic cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9mLUdqLTNTaFB3dlU1VXZic1BSd1ltREV3VjNRRVN0cEZqanVsTmVVOHNCRzNlcjdNNlFzUEE0WXdxS1A1MmZDaEV4RGFIUk9EbWIzSjZ4V3hBWGdackdj?oc=5","date":"2025-01-17","type":"trial","source":"Nature","summary":"Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial - Nature","headline":"Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQZ0Mxa2hpSXlDMk9HZ3FMRnZGM1FPaGFaWGdndTN1UFA0S3l2T3JqOExMSHlzX1lWbjBnU2lvUXZoRHdybHpHZ0JMXzhtMFBPMFVuVjBKSHlHd1JJVkhQZGxOMl9lZExSdXN6THY1QmNIdlp0enYzcTZYRU0wdWx3YVpMUXZkd2xINFpkeFBn?oc=5","date":"2023-06-19","type":"pipeline","source":"Frontiers","summary":"Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency - Frontiers","headline":"Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}